Doxycycline

Generic Name: Doxycycline

Brand Names: Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄N_₂O_₈

CAS Number: 564-25-0

Unique Ingredient Identifier: 334895S862

Background: Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.

Indication: Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:

It is also used to treat infections caused by the following gram-negative microorganisms:

Associated Conditions: Acinetobacter Infections, Anthrax, Bacterial Infection caused by Enterobacter aerogenes, Bartonellosis, Brucellosis, Campylobacter Infection, Chancroid, Chlamydia Trachomatis Infection, Early Lyme Disease, Granuloma Inguinale, Infection Due to Escherichia Coli, Inhalational Anthrax, Klebsiella Infections, Lymphogranuloma Venereum, Malaria caused by Plasmodium falciparum, Nongonococcal urethritis, Plague caused by Yersinia pestis, Psittacosis, Rectal infection caused by Chlamydia Trachomatis, Relapsing fever caused by Borrelia recurrentis, Respiratory Tract Infection Bacterial, Rickettsial infectious disorders, Severe Acne, Sexually Transmitted Infections (STIs), Shigella Infection, Trachoma inclusion conjunctivitis, Tularemia, Vibrio Cholerae Infection, Acute Intestinal amebiasis, Susceptible Bacterial Infections, Uncomplicated endocervical infection, Uncomplicated urethral infection

Associated Therapies: -

Clinical Trials

Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy

Phase 2

Terminated

Conditions: Systolic Heart Failure (NYHA II-III)
Non-ischemic Cardiomyopathy

Interventions: Drug: Doxycycline
Drug: placebo

First Posted Date: 2013-09-05

Last Posted Date: 2014-08-20

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 10

Registration Number: NCT01935622

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease

Phase 2

Conditions: Coronary Aneurysm
Kawasaki Disease

Interventions: Drug: Placebo
Drug: Doxycycline

First Posted Date: 2013-08-07

Last Posted Date: 2019-08-28

Lead Sponsor: Hawaii Pacific Health

Target Recruit Count: 50

Registration Number: NCT01917721

Locations: 🇺🇸
Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States

Low Dose Doxycycline in the Treatment of Corneal Burn

Phase 2

Conditions: Eye Burns

Interventions: Drug: Placebo
Drug: Doxycycline

First Posted Date: 2013-06-26

Last Posted Date: 2013-08-09

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 40

Registration Number: NCT01886560

Locations: 🇨🇳
Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China

Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study

Phase 4

Terminated

Conditions: Chronic Pelvic Pain Syndrome
Bladder Pain Syndrome

Interventions: Drug: placebo
Drug: doxycycline

First Posted Date: 2013-06-18

Last Posted Date: 2015-03-05

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 5

Registration Number: NCT01879930

Locations: 🇨🇭
Dep. of Urology, Bern University Hospital, Berne, Switzerland

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

Phase 2

Completed

Conditions: Colorectal Cancer
Head and Neck Cancer

Interventions: Drug: Doxycycline
Drug: Hydrocortisone 1% cream
Other: Sunscreen
Other: Moisturizer
Drug: Clindamycin
Drug: Medrol-dose pack (Steroid)

First Posted Date: 2013-06-11

Last Posted Date: 2022-12-01

Lead Sponsor: University of Louisville

Target Recruit Count: 24

Registration Number: NCT01874860

Locations: 🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States

Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea

Phase 4

Completed

Conditions: Papulopustular Rosacea

Interventions: Drug: Oracea

First Posted Date: 2013-06-07

Last Posted Date: 2022-08-23

Lead Sponsor: Galderma R&D

Target Recruit Count: 24

Registration Number: NCT01872715

Locations: 🇺🇸
Stephens & Associates Dallas Research Center, Carrollton, Texas, United States

Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

Phase 2

Completed

Conditions: Advanced Malignant Neoplasm
Dermatologic Complication

Interventions: Other: Placebo
Other: Questionnaire Administration
Drug: Doxycycline
Drug: Spironolactone
Procedure: Management of Therapy Complications
Drug: Sunscreen
Drug: Therapeutic Hydrocortisone

First Posted Date: 2013-06-04

Last Posted Date: 2020-01-09

Lead Sponsor: Academic and Community Cancer Research United

Target Recruit Count: 19

Registration Number: NCT01867294

Locations: 🇺🇸
Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States
🇺🇸
Marshfield Clinic, Marshfield, Wisconsin, United States
🇺🇸
Carle Cancer Center, Urbana, Illinois, United States

and more 2 locations